Open Label study of Intracavernous Injection of Alpostadil Alphadex in the Treatment of Erectile Dysfunction

Abstract

The aim of the study was to see the effectiveness of intracavernosal injection of PGE1(alpha-cd, alprostadil alphadex). This study was conducted at Riyadh Care Hospital Saudi Arabia from September 2003 to July 2004, on 18 patients with erectile dysfunction according to inclusion and exclusion criteria. The primary aetiology and contributing factors for erectile dysfunction were noted. Each patient had intracavernous injections of Alprostadil Alphadex (prstaglandin E) starting from minimum 2.5ug to maximum 20ug to maximumm 20ug during titration period in the office. All injections were given on separate occasions, at least one week apart. The patient massaged himself for few second after the injection to help to disperse the drug. Patients were observed for at least thirty minutes following the injection. Vital signs of the patient were measured by the doctor. Intracavernosal alprostadil alphadex injection is an effective, well tolerated and safe therapy for both psychogenic and organic erectile dysfunction.